Sotalol
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | >95% |
| Metabolism | Not metabolised |
| Elimination half-life | 12 hours |
| Excretion | Renal Lactic (In lactating females) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C12H20N2O3S |
| Molar mass | 272.3624 g/mol |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information about Sotalol, click here.
Synonyms / Brand Names: BETAPACE, SOTALOL HYDROCHLORIDE
Overview
Sotalol (trade names Betapace and Betapace AF, Berlex Laboratories) is a drug used in individuals with rhythm disturbances (cardiac arrhythmias) of the heart, and to treat hypertension in some individuals.
Category
Beta Blockers
FDA Package Insert
BETAPACE (sotalol hydrochloride) tablet
Indications and Usage | Dosage and Administration | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Clinical Studies | How Supplied/Storage and Handling | Labels and Packages
 |
SOTALOL HYDROCHLORIDE injection
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages'
 |
Pharmacology
It falls into the class III antiarrhythmic agents because it inhibits the inward potassium ion channels in the heart. It is also a beta blocker because of its primary action on the β-adrenergic receptors in the heart.
By blocking the potassium channels, sotalol prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity.
It also slows atrioventricular (AV) nodal conduction (beta-blocking effect).
Sotalol is a racemic mix of D and L enantiomers. The L isomer is a beta blocker.
Sotalol is not selected for its beta-blocking ability, but rather for its Class III (potassium blocking) properties.
Indications
Sotalol is used to treat ventricular tachycardias as well as atrial fibrillation. Betapace AF is specifically labeled for atrial fibrillation.
Some evidence suggests that sotalol should be avoided in the setting of decreased ejection fraction due to heart attack.
References
See also
- Pages with script errors
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Antiarrhythmic agents
- Beta blockers
- Drugs